Current Health Wearable Monitoring for Advanced Therapies

Current Health was founded in Edinburgh in 2014 to deliver acute and complex care safely outside hospitals. It entered the US in 2019, was acquired by Best Buy in 2021 and was reacquired by its founders in 2025, refocusing on advanced therapies such as CAR-T and bispecifics, which often require long inpatient stays at a few academic centres.

The platform combines an FDA Class II cleared upper-arm wearable that passively tracks respiratory rate, heart rate and HRV, skin temperature, SpO2 and activity with an axillary temperature patch, blood pressure cuff, scale and other peripherals, a cellular home hub and a tablet for video visits and surveys. Machine learning models detect CRS, sepsis and general deterioration earlier, and a 24/7 clinical command center handles escalation. Customers are health systems, community oncology practices and pharma companies running clinical trials.

• Upper-arm wearable: FDA Class II cleared device for respiratory rate, heart rate, HRV, skin temperature, SpO2 and activity.
• Configurable kits: axillary temperature patch, blood pressure cuff, scale, pulse oximeter, glucometer and spirometer.
• Home hub and tablet: cellular connectivity without home Wi-Fi, video visits, symptom surveys and medication reminders.
• AI adverse event detection: models for CRS, sepsis, infection and general deterioration.
• 24/7 clinical command center: remote ICANS assessments and escalation protocols.
• Clinical pathways: more than 50 DRG-specific hospital-at-home pathways ready to deploy.

Oncology centres in Vietnam could monitor patients at home after CAR-T or bispecific infusions with AI alerts for CRS. Private hospital groups could pilot hospital-at-home for heart failure or infection patients to relieve bed pressure. Pharma companies running trials in Vietnam could collect continuous vital sign data from participants at home.

Lets hospitals deliver CAR-T and other complex therapies in ambulatory and home settings instead of long inpatient stays. AI models detect CRS hours earlier than clinical observation alone, supporting earlier intervention. Hospital-at-home customers have run 54,000 episodes, and Mass General Brigham saved 25,000 bed days with a 10.5% readmission rate. Cellular kits, logistics and a 24/7 command center can be fully outsourced, so programmes scale without new beds.

Cell and gene therapies and bispecific antibodies are expanding fast but remain concentrated in a few academic centres because of monitoring needs for CRS and neurotoxicity. Health systems worldwide are shifting acute care into homes to free beds. Vietnam's large cancer centres and private hospital groups are beginning to adopt advanced therapies and face severe bed shortages.

Founded in Edinburgh in 2014; US headquarters in Boston, with engineering and device development in Edinburgh. Acquired by Best Buy in 2021 and reacquired by founders in 2025. Partnered with Sarah Cannon on a multisite outpatient CAR-T programme and with BMS. Wearable is FDA Class II cleared. CEO and co-founder: Chris McGhee.